Trials Sponsors Conditions Drugs Pricing

Conditions

Nasopharyngeal Cancer Neoplasm Metastasis

Outcome Measures

Primary Outcomes (1)

Overall survival
Events of death caused by any reasons
From date of diagnosis until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months

Secondary Outcomes (1)

Progress free survival
From date of diagnosis until the date of first documented progression, assessed up to 36 months

Study Arms (1)

Arm 1

EXPERIMENTAL

4-6 cycles chemotherapy and radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will assigned to those who got PR,SD after chemotherapy.

Radiation: radical radiotherapy

Interventions

radical radiotherapyRadiation

radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will be assigned to those who got PR,SD after chemotherapy.

Arm 1

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 65 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Histologically conformed initial non-keratinizing squamous carcinoma in nasopharynx.
Clinical stages,T1-4N0-3M1，IVc(AJCC 2010).

Sponsors & Collaborators

Zhejiang Cancer Hospital
Otherlead

Study Sites (1)

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, 310000, China

RECRUITING

Shuan HuangCONTACT+8618258111085 huangshuang@zjcc.org.cn

MeSH Terms

Conditions

Nasopharyngeal NeoplasmsNeoplasm Metastasis

Condition Hierarchy (Ancestors)

Pharyngeal NeoplasmsOtorhinolaryngologic NeoplasmsHead and Neck NeoplasmsNeoplasms by SiteNeoplasmsNasopharyngeal DiseasesPharyngeal DiseasesStomatognathic DiseasesOtorhinolaryngologic DiseasesNeoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Shuang Huang, Dr

CONTACT

+8618258111085 huangshuang@zjcc.org.cn

Study Design

Study Type: interventional
Phase: phase 2
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

April 12, 2017

First Posted

April 26, 2017

Study Start

April 14, 2017

Actual (reported)

Primary Completion

April 23, 2023

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

Arm 1

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

Arm 1

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations